A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Introduction Once-weekly semaglutide 1 mg is a novel glucagon-like peptide 1 receptor agonist (GLP-1 RA) that, in the SUSTAIN clinical trials, has demonstrated greater reductions in glycated haemoglobin (HbA1c) and body weight than the other GLP-1 RAs exenatide extended-release (ER) 2 mg, dulaglutid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2020-03, Vol.37 (3), p.1248-1259
Hauptverfasser:	Johansen, Pierre, Sandberg, Anna, Capehorn, Matthew
Format:	Artikel
Sprache:	eng
Schlagworte:	Body Weight Cardiology Cost-Benefit Analysis Diabetes Mellitus, Type 2 - drug therapy Drug Administration Schedule Endocrinology Exenatide - economics Exenatide - therapeutic use Female Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - economics Glucagon-Like Peptides - therapeutic use Glycated Hemoglobin A - analysis Humans Hypoglycemia - chemically induced Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Immunoglobulin Fc Fragments - economics Immunoglobulin Fc Fragments - therapeutic use Internal Medicine Liraglutide - economics Liraglutide - therapeutic use Male Medicine Medicine & Public Health Middle Aged Oncology Original Research Pharmacology/Toxicology Recombinant Fusion Proteins - economics Recombinant Fusion Proteins - therapeutic use Rheumatology United Kingdom Weight Gain
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Once-weekly semaglutide 1 mg is a novel glucagon-like peptide 1 receptor agonist (GLP-1 RA) that, in the SUSTAIN clinical trials, has demonstrated greater reductions in glycated haemoglobin (HbA1c) and body weight than the other GLP-1 RAs exenatide extended-release (ER) 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg. The aim of this analysis was to evaluate the relative cost of control of achieving treatment goals in people with type 2 diabetes (T2D) treated with once-weekly semaglutide versus exenatide ER, dulaglutide and liraglutide from a UK perspective. Methods Proportions of patients reaching HbA1c targets (
ISSN:	0741-238X 1865-8652
DOI:	10.1007/s12325-020-01242-z